Evogene (EVGN) Liabilities and Shareholders Equity (2016 - 2025)
Evogene (EVGN) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $20.0 million as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 49.71% to $20.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $167.1 million through Dec 2025, down 25.18% year-over-year, with the annual reading at $20.0 million for FY2025, 49.71% down from the prior year.
- Liabilities and Shareholders Equity hit $20.0 million in Q4 2025 for Evogene, down from $39.9 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $76.3 million in Q4 2021 to a low of $20.0 million in Q4 2025.
- Historically, Liabilities and Shareholders Equity has averaged $48.7 million across 5 years, with a median of $51.1 million in 2023.
- Biggest five-year swings in Liabilities and Shareholders Equity: increased 6.1% in 2021 and later plummeted 49.71% in 2025.
- Year by year, Liabilities and Shareholders Equity stood at $76.3 million in 2021, then decreased by 26.44% to $56.1 million in 2022, then fell by 8.95% to $51.1 million in 2023, then fell by 21.99% to $39.9 million in 2024, then tumbled by 49.71% to $20.0 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for EVGN at $20.0 million in Q4 2025, $39.9 million in Q4 2024, and $51.1 million in Q4 2023.